Assessment of Factors Associated with PSA Level in Prostate Cancer Cases and Controls from Three Geographical Regions.

Nishi Karunasinghe (n.karunasinghe@auckland.ac.nz)  
University of Auckland

Tsion Zewdu Minas  
National Cancer Institute, NIH

Bo-Ying Bao  
China Medical University

Arier Lee  
University of Auckland

Alice Wang  
University of Auckland

Shuotun Zhu  
University of Auckland

Jonathan Masters  
Whangarei Hospital

Megan Goudie  
Auckland City Hospital

Shu-Pin Huang  
Kaohsiung Medical University Hospital

Frank J. Jenkins  
The University of Pittsburgh Medical Center, Hillman Cancer Center

Lynnette R Ferguson  
FMHS, University of Auckland

Research Article

Keywords: Prostate-specific antigen (PSA) association and correlation, New Zealand, African American, European American, Taiwanese, multiple linear regression, univariate analysis

DOI: https://doi.org/10.21203/rs.3.rs-714389/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Introduction** - It is being debated whether prostate-specific antigen (PSA)-based screening effectively reduces prostate cancer mortality. Some of the uncertainty could be related to deficiencies in the age-based PSA cut-off thresholds used in screening.

**Methods** - Current study considered 2779 men with prostate cancer and 1606 men without a cancer diagnosis, recruited for various studies in New Zealand, US and Taiwan. Association of PSA with demographic, lifestyle, clinical characteristics (for cases), and the *aldo-keto reductase 1C3 (AKR1C3)* rs12529 genetic polymorphisms were analysed using multiple linear regression and univariate modelling.

**Results** - Pooled multivariable analysis of cases showed that PSA was significantly associated with demographic, lifestyle and clinical data with an interaction between ethnicity and age further modifying the association. Pooled multivariable analysis of controls data also showed that demographic and lifestyle are significantly associated with PSA level. Independent case and control analyses indicated that factors associated with PSA were specific for each cohort. Univariate analyses showed a significant age and PSA correlation among all cases and controls except for the US-European cases while genetic stratification in cases showed variability of correlation.

**Conclusion** - Data suggests that unique PSA cut-off thresholds factorized with demographics, lifestyle and genetics may be more appropriate for prostate cancer screening.

Introduction

The serine protease PSA is encoded by the *kallikrein-related peptidase 3 (KLK3)* gene located in chromosomal region 19q13 [1]. This protease is exclusively produced by the glandular prostate epithelium [2], PSA reaches the serum when the microarchitecture of prostate glandular tissue is disrupted [3]. Accordingly, increased level of PSA in serum is an indication of prostate disease or trauma in the prostate gland including prostate cancer.

Since PSA was considered a marker for prostate cancer screening by the US Food and Drug Administration in 1994 [4], US health services had a dedicated prostate cancer screening until the year 2008, when prostate cancer screening with PSA reached a controversial status. This was due to the debate as to whether PSA based screening can help reduce prostate cancer-related mortality in men. Benefits of the PSA biomarker on reducing prostate cancer-related mortality estimated between the European Randomised Study of Screening for Prostate Cancer (ERSPC), and the US Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) trial varied, while both studies identified trial design shortcomings [5–8]. A recent analysis of both ERSPC and PLCO data using the cure parameter estimation calibrated to the ERSPC, projects comparable mortality reductions between the PLCO and the ERSPC trials [9]. In the year 2012, the US Preventive Services Task Force (USPSTF) advised against PSA-based screening for prostate cancer by issuing a grade D recommendation [10]. Comparison of prostate cancer diagnosis data during the pre- and post-USPSTF recommendation eras show that during the latter period US men were diagnosed with more advanced disease compared to the former [11].

Meanwhile, various age-specific PSA thresholds for prostate cancer screening have been used or tested [12]. Literature suggests multiple other factors associated with PSA including BMI [13], tobacco smoking [14–16], alcohol consumption [17], ethnicity [16], and single nucleotide polymorphisms (SNPs) [18]. However, multiple variable factor assessments associated with PSA especially in multiple cohorts from various continents are not found in the literature.

PSA production is signalled by the androgen activated androgen receptors [19]. Androgens are mainly produced in the testicular tissue involving the conversion of androstenedione to androgen catalysed by the *17β-hydroxysteroid dehydrogenase 3* [20]. The relevance of the *aldo-keto reductase 1C3 (AKR1C3)* and its promoter gene polymorphisms in prostate cancer and its catalytic significance in producing extra-testicular androgens are known [21]. PSA level also has an association with the *AKR1C3* rs12529 genetic polymorphism [22]. Other *AKR1C3* genetic polymorphisms have also been associated with benign
prostate hyperplasia-related factors including dihydrotestosterone inactivation and prostate volume \[23\]. Meanwhile, our data suggests that the age-based PSA variation is restricted to the \(AKR1C3\) rs12529 CG and GG genotype carriers in a New Zealand (NZ) prostate cancer cohort \[24\]. In that study, we also showed that ever-smoking influenced both age and PSA at prostate cancer diagnosis among the \(AKR1C3\) rs12529 GG and CG genotype carriers, respectively.

The PSA cut-off thresholds required for prostate screening could differ among different populations and generalised thresholds can cause misjudgement. The current study therefore reports a cross-sectional analysis to understand PSA associations with demographic, lifestyle, and genetic factors (based on the \(AKR1C3\) rs12529 SNPs) in pooled as well as individual case and control cohorts from three geographical regions in the world.

**Material And Methods**

**Participant recruitment and data collection**

Participants assessed in this study were those that were recruited for previous studies from the study locations. Data availability for various study cohorts therefore have similarities as well as differences as follows.

**NZ case control cohorts**

Details of the NZ prostate cancer patient cohort (N=515) considered in this analysis are described in detail elsewhere \[24\]. Patients were recruited between 2006 and 2013 with informed and signed consent (ethics reference NTY/05/06/037 from the Health and Disability Ethics Committees, Ministry of Health, NZ). Patient factors, including self-reported ethnicity, current/former tobacco smoking status and alcohol consumption were recorded at recruitment. Drinking one or more alcoholic drinks per week equivalent to a can of beer, a small glass of wine or a single nip (approximately 20 ml) of spirits categorized men as alcohol consumers. At recruitment, patient heights and weights were measured at the study centre for body mass index (BMI) estimation. Clinical and pathology records of patients were evaluated at the hospital databases to collect age, PSA level, Gleason score and disease stage [tumour-node-metastasis (TNM)] at diagnosis.

All controls (n=572) were NZ-Europeans, recruited for the ‘Optimisation of selenium for health benefits’ study from the Auckland region. This study is registered with the Australian New Zealand Clinical Trial Registry (ANZCTR) \[25\]. These men, self-reported as having no history of cancers (other than non-melanoma skin cancers), and not taking more than 50µg selenium/day as supplements were recruited to this study \[26\]. Participant recruitment was carried out with informed and signed consent (ethics reference NTY/06/07/060, from the Health and Disability Ethics Committees, Ministry of Health, NZ). Recruitment of men to this study started in October 2006 and completed in December 2009. Height and weight of each participant was measured and recorded at study entry, for BMI estimation. These men were of the age range >20y to ≤80y. At study entry, participants completed a health and lifestyle questionnaire that provided information, including age at recruitment, tobacco smoking and alcohol consumption lifestyle. Additionally, they were to provide details of long-term medication used if any, and the disorder being treated. Based on the medication types used and the disorders being treated, they were categorised as having BPH or LUT, cardiovascular disease, diabetes, mental illnesses or other medical conditions. Those not recording use of any medication and have not indicated a health disorder were considered as healthy controls.

In this study, patient risk status was further stratified based on the disease prognostic stage grouping which followed the criteria defined by the 7th edition of the AJCC abbreviated as I, IIA, IIB, III and IV as mentioned previously \[27\].

**US case control cohorts**

The US cohort is part of the NCI-Maryland Prostate Cancer Case-Control Study and has been described previously \[28\]. Recruitment was carried out between 2005 and 2015 under the ethics approval by the Institutional Review Boards at the NCI [protocol # 05-C-N021] and the University of Maryland [protocol #0298229] \[28\]. Of the 976 cases that were recruited into the study, 489 were US-AA and 487 were US-EA. For the study herein, other patient clinical information (age at diagnosis, PSA at
diagnosis, TNM stage and Gleason score at diagnosis) collected from pathology reports and medical records of 202 of these US-AA and 232 US-EA cases were also available for analysis. Disease prognostic stage grouping, and high-risk classification followed the criteria as mentioned before for NZ cases. 486 US-AA and 548 US-EA healthy controls within the age range 47 to 92 were also recruited for the controls arm of the study. All cases and controls self-reported to be either US-AA or US-EA at an interview and signed an informed consent to participate in the study. The interview also evaluated lifestyle factors that included tobacco-smoking habits and alcohol consumption. Alcohol consumers were considered as those consuming more than 12 alcoholic beverages per year, such as beer, wine, wine coolers or liquor. At recruitment, participant were asked their current heights and weights for BMI estimation.

Taiwanese patient cohorts

645 patients with advanced prostate cancer who were on androgen-deprivation therapy (ADT) (TW1 cohort); and 643 patients with localized prostate cancer who underwent RP as initial treatment (TW2 cohort) were recruited between 1995 and 2009. Recruitments were made from three medical centres in Taiwan: Kaohsiung Medical University Hospital, Kaohsiung Veterans General Hospital, and National Taiwan University Hospital, as previously described [29,30]. According to these authors, all TW1 patients have been treated with ADT either with orchiectomy or with luteinizing hormone - releasing hormone agonist, with or without anti-androgen, and were prospectively monitored to evaluate the efficacy of ADT. TW2 patients were treated with RP as initial therapy for localized prostate cancer. Recruitment was carried out under the ethics approval by the Kaohsiung Medical University Hospital (IRB # KMUHIRB-2013132), with informed and signed consent of the patients. At recruitment, patient heights and weights were measured for BMI estimation. Tobacco smoking and alcohol consumption data was not available for these cohorts. Baseline clinical-pathological characteristics (age, PSA level, Gleason score and TNM stage at diagnosis) were collected from patient records. The TNM T2 sub-stage classifications (T2a, T2b and T2c) were not available for the Taiwan cohorts. Although prostate cancer risk status in TW men followed criteria mentioned before under NZ cases, a variation was employed to categorize men carrying TNM stage of T2. Therefore, patients recording a PSA at diagnosis < 20ng/ml or a Gleason sum score < 8 with a ≤ T2 stage were considered as carrying the AJCC prognostic stage grouping <IIB (low-risk disease). TW men with a T3 or T4 stage, or PSA level of ≥20ng/ml, or a Gleason sum score of ≥8 with stage 2 were considered as carrying the prognostic stage grouping >IIB (high-risk disease).

SNP genotyping

Genotype data for the TW1 cases cohorts, the NZ, and US cases cohorts and NZ controls cohort were accessed from previously published studies [22,27,29,31]. SNP genotyping of TW1, NZ and US cases and controls cohorts were performed using protocols described elsewhere [22,27,29]. Genotyping of the TW2 cases cohorts was performed using the Agena Bioscience MassArray iPLEX platform at the National Center for Genome Medicine, Academia Sinica, Taiwan.

PSA measurement of controls

At recruitment, NZ and US controls provided blood samples in BD plain vacutainer tubes. For serum separation, the NZ samples were spun at 2000g for 10 min on an Eppendorf 5810R centrifuge (Hamburg, Germany), while the US samples were spun at 850g for 10 min on a Sorvall T 6000 (Thermo Scientific, New Jersey, USA).

Serum aliquots were stored in -80°C until PSA measurements were made. The total PSA was measured from stored NZ serum aliquots at LabPlus, Auckland, NZ using electro-chemiluminescence immunoassay (Roche Cat. #: 04641655 190) on a Roche Modular E170 analyzer (Roche Diagnostics, NZ). Total assay imprecision was 3.2% at a level of 1.12 ng/mL, 3.7% at 4.61 ng/mL, and 2.7% at 27.5 ng/mL. Serum PSA measurements of US-AA and US-EA controls were obtained using the Human Total Prostate Specific Antigen ELISA Kit from AbCam, ab188388 (Cambridge, United Kingdom). Each sample was measured in duplicate. The average % coefficient of variance was 8.67.

Statistical analysis
The NZ prostate cancer cases cohort consisting of self-identifications exclusive for Māori, Pacific Peoples and East-Asian (n=17) were aggregated as one group (NZ-MPEA) due to their high AKR1C3 rs12529 G allele frequency (85%) recorded in this study. This frequency is comparable to that of the current Taiwan cohort (88%), as well as the East-Asian cohorts reported previously (86%) [32]. The rest of the NZ prostate cancer cohort was aggregated as NZ- non-MPEA group and consisted of New Zealanders self-identified as European, and those from the Indian sub-continent, Middle-East and others (n=498). Participants with current and former tobacco smoking lifestyles were categorized as ever-smokers while the others were considered as never-smokers, without a set threshold. Continuous demographic variables were compared using the Kruskal-Wallis One Way Analysis of Variance on Ranks test, as most data types were not normally distributed. Measurements for non-normally distributed data were provided as medians and 25% and 75% inter quartile ranges. Categorical variables were tested with the Chi Square test. Combined overall PSA data were found to be highly right skewed. Therefore, for the subsequent multiple linear regression analyses, and univariate analyses, PSA data were log transformed. Multiple linear regression analysis was carried out to test the association of PSA with ethnicity, BMI, tobacco smoking, alcohol consumption status, age at recruitment (for controls), age at diagnosis (for cases), disease prognostic stage and Gleason sum score (for cases) and the AKR1C3 rs12529 genotype, as well as for analysing interaction effects. The Spearman Rank Order Correlation was used to analyse the correlation between age and log PSA for all NZ- non- MPEA, US-EA, US AA, TW1 and TW2 cases cohorts and the available controls cohorts with and without genetic stratification. As the NZ- MPEA group consisted of only 17 individuals, they were excluded from all Multiple linear regression and Univariate analyses. Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and SigmaPlot version 14.0 (Systat Software Inc.). A two-sided significance level of P<0.05 was set out for all analyses.

**Results**

**Characteristics of the prostate cancer cohorts**

A comparison of patient characteristics (demographic, lifestyle, and clinical) is given in Supplementary results Table 1a. The Taiwan (TW1-advanced, and TW2 - localized prostate cancer groups respectively) cases showed a significantly lower median BMI (24.2 kg/m² and 24.7 kg/m² respectively) compared to other cases (27.0 kg/m² for NZ, 27.7 kg/m² for US-Africans (US-AA) and 27.5 kg/m² for US-Europeans (US-EA) and P<0.001). The US-AA cases recorded a significantly higher percentage of ever-smokers compared to NZ and US-EA cases (72% vs 56% for NZ and 61% for US-EA and P< 0.00001). The percentage alcohol consumption among NZ cases were significantly lower than the US-AA and the US-EA cases (71% vs 85% for AA and 90% for US-EA and P< 0.00001). Lifestyle data related to tobacco smoking and alcohol consumption are not available for TW1 and TW2 cases.

Median age at prostate cancer diagnosis was significantly higher among TW1 cases compared to NZ, US-AA and US-EA cases (73 y vs 66 y each for NZ and TW2, 63 y for US-AA and 65 y for US-EA and P<0.001). Median PSA at prostate cancer diagnosis was higher among the TW1 and TW2 cases (41 ng/ml and 11 ng/ml respectively vs 8.6 ng/ml for NZ, 7.0 ng/ml for US-AA and 5.8 ng/ml for US-EA and P < 0.001). Median Gleason sum score was the lowest among US-EA cases (6 vs 7 for the NZ, TW1, TW2, and AA cases; P < 0.001). A significantly higher percentage of high-risk prostate cancer with a prognostic stage of >IIB (86%) was recorded among the TW1 cases compared to 29-66% among other cases (TW2, NZ, US-AA and US-EA) (P<0.00001).

Characteristics of the controls cohorts are given in Supplementary results Table 1b. The NZ controls were significantly younger (median 54 y) than the controls from the US (US-AA median 66 y and US-EA median 64 y, <0.001). Significantly, different BMI values were recorded between the three cohorts with US-AA recording the highest median of 29 kg/m² and NZ and US-EA controls recording medians of 26 and 27.4 kg/m² respectively. Significantly different proportions of ever-smokers were recorded between the three controls cohorts with only 34% among NZ controls while US-AA and US-EA controls recorded 61% and 59% respectively. Median PSA at recruitment was also significantly different between the three controls cohorts (NZ-0.9 ng/ml, US-AA-0.4ng/ml and US-EA- 0.4ng/ml). Among NZ controls, 60.8% have recorded no medication intake for any
health disorder, while 21% were taking medication for cardiovascular disease, 1% for diabetes, 5.8% for benign prostatic hyperplasia / lower urinary tract infection (BPH/LUT), 3.7% for mental illnesses, and 8.2% for other health disorders.

**AKR1C3 rs12529 genetic polymorphism distribution among the cohorts**

The AKR1C3 rs12529 genotype data for a total of 366, 202, 232, 618 and 643 of cases from NZ-non-MPEA, US-AA, US-EA, TW1 and TW2 cohorts respectively, 13 NZ-MPEA cases and 454 from NZ controls are presented in Supplementary results Table 2.

**A. Multiple variable testing on log PSA outcomes**

I. Testing the association of log PSA on multiple variables among pooled cases.

I.a. A summary of the association of log PSA with ethnicity, disease prognostic stage, Gleason sum score, age at diagnosis, BMI and genotype for cases cohorts analysed with or without lifestyle factors is given in Table 1. Log PSA showed a significant association with all tested factors except for the genotype when analysed without lifestyle factors. The US-AA, NZ-non-MPEA, TW1 and TW2 cases cohorts showed a higher log PSA compared to that of the US-EA cohort. BMI showed a significant negative association on log PSA while the other variables showed a positive association.

When lifestyle factors of tobacco smoking and alcohol consumption were included in the model, log PSA showed a significant association with ethnicity, disease prognostic stage, Gleason sum score, age at diagnosis and smoking status. In this analysis too, genotype showed no association on log PSA. Alcohol consumption also showed no significant association with log PSA outcomes. The log PSA association with BMI was not significant in this analysis compared to the analysis which included TW cases, but without inclusion of lifestyle data.

**Table 1. Results summary of multiple linear regression analyses for testing impacts of demographic, genetic, lifestyle and clinical parameters on log PSA for all cases cohorts.**


### Table 2. Statistical outcomes in the interactive model with age at diagnosis and ethnicity on log PSA outcome for US-EA, US-AA and NZ- non-MPEA cases cohorts.

| Parameter | Parameter | Pr > F | Parameter | Parameter | Pr > F |
|-----------|-----------|--------|-----------|-----------|--------|
| Ethnicity (ref=European American) | <.0001 | Ethnicity (ref=European American) | 0.0002 |
| African American | 0.35 | African American | 0.36 |
| NZ-non MPEA | 0.29 | NZ-non MPEA | 0.24 |
| Taiwanese TW1 | 1.69 |
| Taiwanese TW2 | 0.51 |
| Prognostic Stage (ref=<IIB) | <.0001 | Prognostic Stage (ref=<IIB) | <.0001 |
| >IIB | 0.55 | >IIB | 0.33 |
| Gleason sum score | 0.18 | <.0001 | Gleason sum score | 0.27 | <.0001 |
| Genotype (ref=CC) | 0.678 | Genotype (ref=CC) | 0.653 |
| G | -0.02 |
| GG | 0.04 | GG | 0.069 |
| Age at diagnosis | 0.01 | 0.0004 | Age at diagnosis | 0.01 | 0.003 |
| BMI | -0.02 | 0.004 | BMI | -0.01 | 0.136 |
| Ever-smoker (ref=never smoker) | 0.16 | 0.015 |
| Alcohol consumer (ref= never alcohol consumer) | -0.07 | 0.370 |
| Model | R^2=0.396, Pr>F <0.0001 | Model | R^2=0.187, Pr>F <0.0001 |

*- Ever-smoker and alcohol consumer lifestyle data are not available for Taiwanese (TW) cohorts.

NZ- non MPEA cases – New Zealanders self-identified as European, or from the Indian sub-continent, Middle-East and others.

1.b. Interactive effects on log PSA

Multiple linear regression for the interactions between age at diagnosis, lifestyle, genetics and ethnicity in the log PSA outcomes were analysed. However, except for the age at diagnosis and ethnicity two-way interaction (Table 2), the interactions between ethnicity and ever-smoking status or ethnicity and alcohol consumption status or the three-way interaction between age at diagnosis, ethnicity and genotype were not significantly associated with log PSA (Supplementary results Tables 3). However, the age at diagnosis*ethnicity interaction remained significant even under the three-way model.
| Source                                      | DF | Type III SS | Mean Square | F Value | Pr > F |
|---------------------------------------------|----|-------------|-------------|---------|--------|
| age at diagnosis*ethnicity interaction      |    |             |             |         |        |
| Ethnic Group                                | 2  | 5.38        | 2.69        | 3.33    | 0.036  |
| Prognostic stage                            | 1  | 17.43       | 17.43       | 21.56   | <.0001 |
| Gleason sum score                           | 1  | 36.93       | 36.93       | 45.69   | <.0001 |
| Genotype                                    | 2  | 0.66        | 0.33        | 0.41    | 0.667  |
| Age at diagnosis                            | 1  | 7.51        | 7.51        | 9.28    | 0.002  |
| BMI                                         | 1  | 1.85        | 1.85        | 2.29    | 0.130  |
| Smoker                                      | 1  | 4.99        | 4.99        | 6.17    | 0.013  |
| Alcohol                                     | 1  | 0.60        | 0.60        | 0.75    | 0.388  |
| Age at diagnosis*Ethnic Group               | 2  | 8.08        | 4.04        | 5       | 0.007  |

NZ- non MPEA cases – New Zealanders self-identified as European, Indian sub-continent, Middle-East and others

II. The association of log PSA with multiple variables in independent cases cohorts

As cases data showed a significant interaction of age at diagnosis and ethnicity with log PSA outcomes, all cases cohorts were also analysed independently with multiple linear regression. Independent cases cohorts assessed with multiple linear regression analysis (Table 3) indicate that log PSA is significantly associated with Gleason sum score for US-EA cases; Gleason sum score and BMI for US-AA cases; prognostic stage, age at diagnosis and tobacco smoking for NZ-non-MPEA cases; prognostic stage and BMI for TW1 cases and prognostic stage and Gleason sum score for TW2 cases.

Table 3. The association of log PSA with age, BMI, clinical data, lifestyle and genotype for US-EA, US-AA and NZ-non-MPEA cases cohorts analysed independently.

NZ- non MPEA cases – New Zealanders self-identified as European or from the Indian sub-continent, Middle-East and others.

III. The association of log PSA with multiple variables among pooled controls

Multiple regression analysis showed that log PSA is significantly associated with ethnicity, age, BMI and smoking status when all controls cohorts were considered together (Table 4).

Table 4. Results of multiple linear regression analysis for testing impacts of age, BMI, and lifestyle on log PSA for all controls cohorts.
### Parameter Estimation Table

| Parameter | European American | African American | NZ- non-MPEA | TW1 | TW2 |
|-----------|-------------------|------------------|--------------|-----|-----|
| Prognostic Stage ≥IIB (ref=IIB) | 0.13 | 0.310 | 0.22 | 0.179 | 0.62 | <.0001 | 1.79 | <.0001 | 0.35 | 0.0003 |
| Gleason sum score | 0.26 | 0.001 | 0.62 | <.0001 | 0.07 | 0.208 | 0.08 | 0.098 | 0.12 | 0.006 |
| Genotype (ref=CC) for all except TW (ref=CG) | 0.361 | 0.720 | 0.778 |
| CG | 0.08 | -0.047 | -0.07 | 0.00 | 0.117 | 0.00 | 0.666 |
| GG | 0.024 | 0.105 | -0.01 | -2.35 | 0.44 |
| Age at diagnosis | 0.01 | 0.491 | 0.02 | 0.073 | 0.02 | 0.0003 | -0.02 | 0.894 | 0.01 | 0.186 |
| BMI | -0.01 | 0.587 | -0.04 | 0.012 | 0.01 | 0.259 | -0.06 | 0.006 | 0.01 | 0.659 |
| Ever-smoker (ref=never smoker) | 0.16 | 0.697 | 0.13 | 0.697 | 0.22 | 0.018 |
| Alcohol consumer (ref= never alcohol consumer) | -0.07 | 0.595 | 0.21 | 0.325 | -0.15 | 0.139 |
| Model | R^2=0.08, Pr>F <0.013 | R^2=0.336, Pr>F <0.0001 | R^2=0.206, Pr>F <0.0001 | R^2=0.23, Pr>F <0.0001 | R^2=0.111, Pr>F <0.0001 |

### IV. The association of log PSA with multiple variables in independent controls cohorts.

When the control cohorts were independently analysed with multiple linear regression analysis (Table 5), age was significantly associated with log PSA in US-EA, US-AA and NZ controls. However, in US-EA and US-AA controls, log PSA was significantly associated also with BMI, while among US-AA controls, tobacco smoking was also a significant association factor.
Table 5. Summary of multiple linear regression analysis for testing impacts of age, BMI, and lifestyle on log PSA for US-EA, US-AA and NZ-European controls analysed independently.

| Parameter | European American | African American | NZ-European |
|-----------|-------------------|------------------|--------------|
| Age       | 0.03              | 0.05             | 0.03         |
| Pr > F    | <.0001            | <.0001           | <.0001       |
| BMI       | -0.02             | -0.03            | -0.01        |
| Pr > F    | 0.048             | 0.008            | 0.2039       |
| Ever-smoker (ref=never-smoker) | -0.18 | -0.25 | 0.04 |
| Pr > F    | 0.072             | 0.034            | 0.6255       |
| Ever alcohol consumer (ref= never alcohol consumer) | 0.13 | 0.09 | -0.19 |
| Pr > F    | 0.389             | 0.4812           | 0.0785       |

B. Univariate analyses on log PSA correlation with age

As ethnicity interacting with age was the most influential factor that produced an impact on log PSA, we further attempted univariate analyses to understand age dependent impacts on log PSA levels with and without stratification by genotype for independent case and control cohorts (Table 6). Overall, all controls (NZ, US-EA, US-AA) and all cases except for the US-EA cases showed significant correlation between age and log PSA. A reduction in correlation coefficient strength was observed among cases compared to controls overall. The NZ control cohort showed significant age and log PSA correlation despite stratification by genotype. However, NZ-non-MPEA cases showed significant age and log PSA correlation only among those carrying the AKR1C3 rs12529 CG and GG genotypes. For US-AA cases, significant age and log PSA correlation was restricted to those carrying the AKR1C3 rs12529 CC and CG genotypes. For TW1 and TW2 cases, this correlation was restricted to men carrying the AKR1C3 rs12529 GG genotype, while for the US-EA cases, none of the AKR1C3 rs12529 genotypes showed significant correlations.

Table 6. Spearman correlation statistics between Age (age at diagnosis for cases and age at recruitment for controls) and log PSA stratified by ethnicity, case, control status and the AKR1C3 rs12529 genotype.

| r = correlation coefficient; p = significance of probability; n= number of pairs tested |
|-------------------------------------------------------------------------------------|
| NZ- non MPEA cases – New Zealanders self-identified as European, or from the Indian sub-continent, Middle-East and others. |

Discussion

A significant difference in BMI was observed in cases and controls of each tested ethnic group. The current ever-smoker proportion of men among US-AA and US-EA cases and controls are higher than those of the proportions recorded by others for 2001–2012 period [33]. The current NZ cases cohort had a higher (56%) and the current NZ controls recorded a lower (34%) proportion of ever-smokers than 2011/2012 cohorts reported before [34]. The percentage of men recording alcohol consumption between NZ, US-AA and US-EA cohorts (both cases and controls) were significantly different. However, due to the variation of alcohol consumption criteria between NZ and US cohorts, comparison of these statistics is not possible. The clinical characteristics also varied between the tested cases cohorts. The TW1 cohort recorded the highest proportion (86%) of high-risk prostate cancers as expected, as this group was particularly recruited as an advanced prostate cancer category. The proportion of high-risk prostate cancers between NZ (51%) and US-EA (54%) cohorts were comparable; while the comparatively higher proportion of 66% high-risk prostate cancers recorded from the US-AA cohort was as expected [35]. The comparatively lower proportion of 29% of high-risk cases recorded from TW2 is due to recruitment of cases to this cohort particularly with localized prostate cancer category. A previous study with US-AA controls between ages 40–79 y without
|                        | All     | CC     | CG     | GG     |
|------------------------|---------|--------|--------|--------|
| NZ European controls   | r 0.556 | 0.517  | 0.519  | 0.616  |
|                        | p 2E-07 | 2E-07  | 2E-07  | 2.26E-09 |
|                        | n 498   | 181    | 202    | 71     |
| NZ - non MPEA cases    | r 0.303 | 0.129  | 0.287  | 0.426  |
|                        | p 6.67E-011 | 0.160 | 2.33E-04 | 7.43E-05 |
|                        | n 449   | 120    | 161    | 82     |
| US-AA controls         | r 0.344 |        |        |        |
|                        | p 1.09E-12 |      |        |        |
|                        | n 410   |        |        |        |
| US-AA cases            | r 0.243 | 0.312  | 0.239  | 0.153  |
|                        | p 4.98E-04 | 0.017 | 0.014  | 0.349  |
|                        | n 202   | 58     | 105    | 39     |
| US-EA controls         | r 0.213 |        |        |        |
|                        | p 2.89E-06 |      |        |        |
|                        | n 475   |        |        |        |
| US-EA cases            | r 0.0244 | 0.113 | -0.063 | 0.110  |
|                        | p 0.711 | 0.352  | 0.504  | 0.457  |
|                        | n 232   | 69     | 115    | 48     |
| TW1 cases              | r 0.119 | 0.500  | -0.00108 | 0.140  |
|                        | p 0.003 | 0.182  | 0.990  | 0.002  |
|                        | n 622   | 8      | 133    | 477    |
| TW2 cases              | r 0.113 | 0.0286 | 0.103  | 0.121  |
|                        | p 0.005 | 1.000  | 0.217  | 0.008  |
|                        | n 622   | 6      | 144    | 472    |

prostate cancer recruited between mid-late 1990s has recorded a median PSA of 0.83 ng/ml [36]. A predominantly US-EA controls cohort from the Physicians’ Health Study recruited in the pre-PSA era 1982–1984, within the age range 40–59 y, median PSA ranged from 0.89 to 1.04 ng/ml [37]. The relatively higher PSA levels previously recorded for US-EA and US-AA controls either in the pre- or early PSA era being comparable to the PSA level of the current NZ-European controls may be a consequence of low level of PSA-based prostate cancer screening and subsequent procedures in prostate cancer diagnosis in NZ as recorded previously [27, 38].

Our multiple linear regression model that included prostate cancer cases from multiple ethnic groups indicated that log PSA is directly associated with ethnicity, age at diagnosis and clinical factors and inversely with BMI, while the genotype showed no effect. When lifestyle factors were included in the model using the cases cohorts from US-EA, US-AA and NZ-non-MPEA, log PSA was shown to be directly associated with ethnicity, age at diagnosis, clinical factors, and tobacco smoking, but not with BMI. This may be due to sample size reduction after TW cases elimination reducing statistical power. In the independent cohort analyses of cases data, we noted that parameters that significantly associate with log PSA varied with each cases cohort. US-EA and US-AA cases showed log PSA association with Gleason sum score. For the US-AA cases represented by 66% high-risk cases, and TW1 cases represented by 86% high-risk cases, BMI was a significant inverse factor for log PSA outcomes. For NZ-non-MPEA cases, disease prognostic stage, age at diagnosis and tobacco smoking had significant association with log PSA level. Impact of tobacco smoking on PSA in NZ men have been reported before [22]. The inverse association of log PSA with tobacco smoking seen in the current combine controls as well as independent US-AA controls recorded in our analyses is comparable with previous studies [16]. Contradictory nature of tobacco smoking impacts on log PSA among cases and controls in the current assessment require explanation. One possibility is that within a tumour environment, controlling further tissue damage caused by tobacco smoke constituents could be restrictive leading to increased leaching of PSA to the circulation. NZ men smoke cigarettes containing an unusually high content of polycyclic aromatic hydrocarbons (PAHs) and nicotine [39]. Influence of PAHs and its metabolism by AKR1C3 producing reactive metabolites such as O-quinones and subsequent
oxidative DNA damage, DNA adduct formation, DNA lesions and mutations have been reviewed before\(^{[40]}\). Therefore, the positive association of log PSA on ever-smoking in NZ-non-MPEA cases may at least partially, be due to this exposure to high PAH content. As AKR1C3 enzyme catalyses both extra-testicular androgen synthesis and metabolism of PAHs derived from tobacco smoke exposure\(^{[21]}\), negative association of log PSA with tobacco smoking is also a possibility if the PAH metabolism is given priority over androgen synthesis.

It is interesting to note that the US-EA and US-AA cases cohorts who were diagnosed at a relatively lower median PSA level than the NZ-non-MPEA cases, log PSA was associated with Gleason sum score, while the NZ-non-MPEA and the TW1 cases diagnosed with relatively higher PSA levels, log PSA was associated with the prognostic stage. The TW2 cases, although diagnosed with a relatively higher PSA level than the US-EA, US-AA and NZ-non-MPEA cases, and carrying only 29% of high-risk cases, log PSA is associated with both Gleason sum score and prognostic stage. In these multivariable linear regression models, log PSA was not associated with age at diagnosis in US-EA, US-AA, TW1 and TW2 cases cohorts when analysed independently. Whether it is a true effect or due to reduced sample sizes when independent analyses were performed is hard to infer.

When controls from US-EA, US-AA, and NZ-Europeans were analysed together using multiple linear regression, log PSA was significantly associated with ethnicity, age, BMI and tobacco smoking lifestyle. However, when the controls cohorts were independently analysed, US-AA controls retained the significant log PSA association with age, BMI and tobacco smoking, while in US-EA, this was limited to age and BMI and for NZ-European controls this was limited to age only. Significant inverse log PSA association with BMI in US-AA cases and US-EA and US-AA controls could be indicating a possibility of BMI being indirectly involved in prostate health in US cohorts. It is also known that US-AA men present more aggressive prostate cancers than the US-EA men\(^{[41]}\). The average baseline BMI of predominantly US-EA men with a mean age of 65 y, in 1993–1996 was 26 kg/m\(^2\)\(^{[42]}\). Among these men those who remained prostate cancer free were with baseline BMI ranging from 25.5–25.9 kg/m\(^2\) while those who developed advanced prostate cases were with a baseline of 25.8 kg/m\(^2\)\(^{[42]}\). Comparison of current data with that of the mid 1990s, there is an increase in BMI by around 1.5 kg/m\(^2\) among US-EA cases and controls. Among the current NZ-non-MPEA cases cohort, median BMI was 1 kg/m\(^2\) higher than that of the current NZ-European controls cohort. As BMI is significantly and inversely associated with log PSA levels in some of the analysed cohorts, there is a possibility of higher BMI masking early diagnosis of prostate cancer by PSA screening in these cohorts\(^{[43]}\). Log PSA was significantly and inversely associated with BMI also in the TW1 cases cohort with advanced stages of prostate cancer receiving ADT. This BMI association with log PSA might have some relevance to ADT associated BMI increases in this cohort\(^{[44]}\). It is a possibility that BMI and associated inverse log PSA is unique to certain populations such as the current US-AA cases and US-AA and US-EA controls, indicative of a unique aetiology towards prostate health outcomes in these men. At the time the US Food and Drug Administration approved PSA to be used for prostate cancer screening in 1994\(^{[45]}\), predominantly US-EA men were with a mean BMI of 26 kg/m\(^2\)\(^{[42]}\). It is possible that in mid 1990s age-based increase in PSA was a valid concept in US prostate cancer cohorts, although not so in the recent prostate cancer study cohorts from US with relatively higher BMI.

All controls and prostate cancer cases except for the US-EA cases showed a significant correlation between age (at diagnosis for cases and at recruitment for controls) and log PSA based on a univariate analysis model. Compared to controls, cases showed a weakened but significant correlation in NZ-non-MPEA, and US-AA men while in US-EA cases this correlation was completely lost. It is known that serum PSA increase is not a specific marker for prostate cancer as it also increases with conditions such as BPH\(^{[18]}\). As the NZ controls consisted of only 5.8% of men with BPH/LUT, the age-associated increase in serum PSA in this cohort can be assured as predominantly due to age rather than due to urological disorders.

Our previous studies have reported that men carrying the AKR1C3 rs12529 CC genotype carry an increased recording of high-risk or advanced prostate cancer in NZ and TW men\(^{[29,31]}\). Regardless of stratification by the AKR1C3 rs12529 genetic polymorphism, NZ-European controls and NZ-non-MPEA cases carrying the AKR1C3 rs12529 CG and GG genotypes retained a significant correlation between age at diagnosis and log PSA, while this was lost in NZ-non-MPEA cases carrying the CC genotype. Among both NZ-non-MPEA cases and NZ-European controls, the strongest correlation between age and log PSA
was recorded among those carrying the AKR1C3 rs12529 GG genotype. Among TW1 and TW2 cases cohorts, genetic stratification resulted in those carrying the AKR1C3 rs12529 GG genotype retaining a significant correlation between the age at diagnosis and log PSA. Therefore, it seems that patients carrying the AKR1C3 rs12529 CC genotype from NZ-non-MPEA, and CC and CG genotype carriers of TW, GG genotype carriers of US-AA and all US-EA cases carry prostate cancer phenotypes, without an association with age at diagnosis and PSA. It is interesting to note that the TW1 cases carrying the AKR1C3 rs12529 GG genotype carry a significant age at diagnosis and log PSA correlation similar to the NZ-non-MPEA cases regardless of the fact that the former has been diagnosed at a significantly higher age, PSA level, and prognostic stage while also recording a significantly lower BMI. Even the TW2 cases with the AKR1C3 rs12529 GG genotype carry a significant age at diagnosis and log PSA correlation despite being different to the TW2 cases having lower proportions of men with high-risk disease. AKR1C3 is known as an epithelial-mesenchymal transition driver in prostate cancer metastasis [46]. In a small group of men with prostate cancer from NZ, we have shown a significant increase in leukocyte AKR1C3 activity level with age at diagnosis, and upon genetic stratification this shows a trend among cases carrying the AKR1C3 rs12529 GG genotype only [24]. Additionally, our previous study showed that men carrying the AKR1C3 rs12529 GG genotype carry higher levels of leukocyte AKR1C3 activity, if their PSA was > 20ng/ml, compared to those carrying a PSA level ≤ 20ng/ml. It is a possibility that the AKR1C3 rs12529 GG genotype carriers among NZ cases with an increasing trend of age dependent AKR1C3 activity and are exposed to more reactive O-quinone formation due to smoking habits, could lead to increased ROS production as they age. This could result in increased DNA damage in tissue including that of the prostate glandular epithelium with subsequent increases in serum PSA levels. Our previous analysis showed that men carrying the AKR1C3 rs12529 GG genotype and are ever-smokers are diagnosed at a higher age compared to the same genotype carriers who are never-smokers; and men carrying the AKR1C3 rs12529 CG genotype and ever-smokers are diagnosed at a higher PSA level compared to the same genotype carriers who are never-smokers [24].

If the current tested cases and controls cohorts have sufficiently represented the general NZ, US and TW men, the current findings pose the question of validity of the age-based PSA thresholds to be used in prostate cancer screening of all US-EA men or the specific AKR1C3 rs12529 genotype stratified groups in NZ, US-AA, and TW men. The strength of age and log PSA correlation generally diminishing from controls to cases in all cohorts in univariate model could also mean the irregularity of this correlation with prostate cancer manifestation and progression.

Among the shortcomings of the current study, are the relatively small sample sizes from NZ, US-AA, US-EA that diminishes statistical power with stratified analyses. As this study utilized data from previous studies, the consistency of data availability was limited. Such deficiencies include the absence of controls among TW men; absence of clinical and prognostic data in a substantial proportion of US and NZ cases; and aspects such as the alcohol consumption data between NZ and US cohorts being not comparable. The absence of tobacco smoking and alcohol consuming lifestyle data from the TW cohorts also added to the restrictions in understanding lifestyle effects among this East-Asian cohort. The TW cohorts also lacked the TNM stage 2 sub-classifications. Therefore, a proportion of cases with T2 stage and having a PSA < 20 ng/ml and a Gleason sum score of < 8 would have wrongfully considered as low risk at prognostic staging. The significant demographic, lifestyle, clinical and prognostic variability between NZ, US and TW cases cohorts also limits the strength of the current findings. For example, NZ and US cases consisted of men encompassing the entire spectrum of the disease. However, TW1 and TW2 cases cohorts had distinct clinical differences. Additionally, NZ and US-AA and US-EU cases cohorts with a relatively lower median PSA levels < 10ng/ml may represent individuals seen either in screening or early detection programs, characteristic of Western Countries. Compared to that PSA examination based prostate screening is not included in the periodic comprehensive medical examination in Taiwan [47].

**Conclusion**

The well-known PSA association with age (age at diagnosis for cases and age at recruitment for controls) was reproduced in combined cross-sectional analyses with multiple linear regression in both cases and controls. However, upon analyses of independent cases cohorts this was reproduced only among NZ-non-MPEA cases. Among controls, PSA was significantly
associated with age in all tested cohorts with independent analyses as well as when tested as a pooled group. This indicates that changes have taken place impacting general PSA increase with age upon cancer presentation in some groups. Association of PSA with BMI and tobacco smoking at the expense of age in tested case control cohorts could be indicating a changing paradigm of parameters associated with PSA since this test was established for prostate cancer screening. As the BMI is increasing in most populations with a Western lifestyle, there is a possibility that beyond a median BMI of 27 kg/m^2 (as reported in the current NZ cases), the ability to be screened with age-based PSA thresholds for prostate cancer could be impaired. Our data suggests that PSA thresholds for prostate cancer screening need refreshing in different ethnicities, in different geographical locations, at different time points for its better utility. However, it is too early to know whether the current findings on variable factors affecting PSA outcomes in this cross-sectional analysis are unique only to the current tested cohorts or whether they can be generalized to these ethnicities from different geographical locations. The current findings require further validation with extended and comparable cohorts that will provide better statistical power for stratified analyses based on BMI, lifestyle factors and genotype, as well as to reach conclusions that are more robust.

**Declarations**

**Author Contributions**

N.K.-Conceptualization, methodology and manuscript writing; T.Z.M., B.B., A.L, A.W., S.Z., J.M., M.G., S.H., F.J.J., and L.R.F-Supported with methodology and manuscript editing. All authors have read and agreed to the submitted version of the manuscript.

**Availability of materials and data**

**Data availability**

Data related to this manuscript is available as a supplementary Microsoft Excel file.

**Supplementary results tables**

Supplementary results Table 1a. Comparison of prostate cancer cases characteristics of cohorts from NZ, TW and US.

Supplementary results Table 1b. Characteristics of the control study cohorts from NZ and US.

Supplementary results Table 2. Comparison of the AKR1C3 rs12529 genotype frequencies among cohorts.

Supplementary results Table 3. Statistical outcomes in the models with the two-way smoker*ethnicity interaction and alcohol*ethnicity interaction, and the three-way interaction between age at diagnosis*ethnicity*genotype for US-EA, US-AA and NZ-non MPEA cases cohorts.

**Additional information**

**Funding**

Authors wish to acknowledge the following grantees from NZ for their support with the study since 2006 - the A+ Trust, Auckland District Health Board, Auckland, NZ (Grant No. 5461-PG-1204-007), the GoodFellow Trust, Urology Department, Auckland Hospital, Auckland, NZ (Grant No. +3192), the Cancer Society NZ (Grant No. 10/08); and the Auckland Northland Cancer Society, NZ. The US case control study was supported by the Intramural Research Program of the Center for Cancer Research (ZIA BC010499 and ZIA BC010624). The TW study was supported by the Ministry of Science and Technology of Taiwan (Grant No. 108-2314-B-037-026-MY2 and 108-2320-B-039-050-MY3), the Kaohsiung Medical University Hospital (Grant No. KMUH108-8R53 and KMUH108-8R55), and the China Medical University (Grant No. CMU108-MF-50 and CMU109-MF-65).

**Disclosures and Conflict of interests**
Authors confirm that all methods were carried out in accordance with relevant guidelines and regulations.

Authors confirm that there are no disclosures or conflicts of interests in relation to this manuscript financial or otherwise.

**Acknowledgements**

Stefan Ambs PhD MPH, Senior Investigator and Head, Molecular Epidemiology Section, Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD, USA is sincerely acknowledged for his support in organising the data access of the US-EA and US-AA prostate cancer cases and controls cohorts, as well as his constructive comments on this manuscript. We sincerely acknowledge contribution by the patient and control volunteers.

**References**

1. Riegman, P. H., Vlietstra, R. J., Suurmeijer, L., Cleutjens, C. B. & Trapman, J. Characterization of the human kallikrein locus. *Genomics* **14**, 6-11, doi:10.1016/s0888-7543(05)80275-7 (1992).

2. Bjartell, A. *et al.* Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. *Urology* **42**, 502-510 (1993).

3. Prcic, A., Begic, E. & Hiros, M. Usefulness of Total PSA Value in Prostate Diseases Diagnosis. *Acta Inform Med* **24**, 156-161, doi:10.5455/aim.2016.24.156-161 (2016).

4. Ablin, R. J. & Haythorn, M. R. Screening for prostate cancer: Controversy? What controversy? *Curr Oncol* **16**, 1-2, doi:10.3747/co.v16i3.459 (2009).

5. Andriole, G. L. *et al.* Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. *J. Natl. Cancer Inst.* **104**, 125-132, doi:10.1093/jnci/djr500 (2012).

6. Gulati, R. *et al.* The impact of PLCO control arm contamination on perceived PSA screening efficacy. *Cancer Causes Control* **23**, 827-835, doi:10.1007/s10552-012-9951-8 (2012).

7. Schroder, F. H. ERSPC, PLCO studies and critique of cochrane review 2013. *Recent Results Cancer Res* **202**, 59-63, doi:10.1007/978-3-642-45195-9_7 (2014).

8. Hugosson, J. *et al.* A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. *Eur Urol* **76**, 43-51, doi:10.1016/j.eururo.2019.02.009 (2019).

9. de Koning, H. J. *et al.* The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. *Cancer* **124**, 1197-1206, doi:10.1002/cncr.31178 (2018).

10. Moyer, V. A. & Force, U. S. P. S. T. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* **157**, 120-134, doi:10.7326/0003-4819-157-2-201207170-00459 (2012).

11. Gejerman, G. *et al.* US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses. *Investig Clin Urol* **58**, 423-428, doi:10.4111/icu.2017.58.6.423 (2017).

12. Gilbert, R. *et al.* Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. *Cancer Causes Control* **29**, 383-388, doi:10.1007/s10552-018-1014-3 (2018).

13. Harrison, S. *et al.* Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. *Cancer Causes Control* **31**, 431-449, doi:10.1007/s10552-020-01291-3 (2020).

14. Tarantino, G. *et al.* Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study. *Future Sci OA* **7**, FSO643, doi:10.2144/fsoa-2020-0154 (2021).

15. Press, D. J. *et al.* Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. *Prev Med Rep* **20**, 101174, doi:10.1016/j.pmedr.2020.101174 (2020).
16. Gelmann, E. P. et al. Relationship of demographic and clinical factors to free and total prostate-specific antigen. *Urology* **58**, 561-566, doi:10.1016/s0090-4295(01)01305-x (2001).
17. Zuccolo, L. et al. Alcohol consumption and PSA-detected prostate cancer risk–a case-control nested in the ProtecT study. *Int J Cancer* **132**, 2176-2185, doi:10.1002/ijc.27877 (2013).
18. Gudmundsson, J. et al. Genetic correction of PSA values using sequence variants associated with PSA levels. *Sci Transl Med* **2**, 62ra92, doi:10.1126/scitranslmed.3001513 (2010).
19. Kim, J. & Coetzee, G. A. Prostate specific antigen gene regulation by androgen receptor. *J Cell Biochem* **93**, 233-241, doi:10.1002/jcb.20228 (2004).
20. Werner, R. et al. Testosterone synthesis in patients with 17beta-hydroxysteroid dehydrogenase 3 deficiency. *Sex Dev* **6**, 161-168, doi:10.1159/000336605 (2012).
21. Karunasinghe, N., Masters, J., Flanagan, J. U. & Ferguson, L. R. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review. *Curr Cancer Drug Targets* **17**, 603-616, doi:10.2174/1568009617666170330115722 (2017).
22. Karunasinghe, N. et al. Androgen pathway related gene variants and prostate cancer association in Auckland men *Curr Pharmacogenomics Person Med* **11** 22-30, doi:10.2174/10022 (2013).
23. Roberts, R. O. et al. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia. *Prostate* **66**, 392-404, doi:10.1002/pros.20362 (2006).
24. Karunasinghe, N. et al. Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand. *PLoS One* **14**, e0217373, doi:10.1371/journal.pone.0217373 (2019).
25. Karunasinghe, N. & Ferguson, L. R. Supplementation of 200 micro grams/d selenium as selenized yeast for six months in a male cohort from Auckland, New Zealand to be monitored with biomarker variation with and without genetic stratification. ,<http://www.ANZCTR.org.au/ACTRN12619001106123.aspx> (2019).
26. Karunasinghe, N. et al. Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand. *Genes Nutr* **7**, 179-190, doi:10.1007/s12263-011-0259-1 (2012).
27. Karunasinghe, N. et al. Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts. *PLoS One* **13**, e0199122, doi:10.1371/journal.pone.0199122 (2018).
28. Smith, C. J. et al. Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men. *Cancer Epidemiol Biomarkers Prev* **26**, 845-853, doi:10.1158/1055-9965.EPI-16-1027 (2017).
29. Yu, C. C. et al. Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. *PLoS One* **8**, e54627, doi:10.1371/journal.pone.0054627 (2013).
30. Huang, S. P. et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. *Cancer Epidemiol Biomarkers Prev* **18**, 3068-3074, doi:10.1158/1055-9965.EPI-09-0665 (2009).
31. Vaidyanathan, V. et al. Environmental factors and risk of aggressive prostate cancer among a population of New Zealand men - a genotypic approach. *Mol Biosyst* **13**, 681-698, doi:10.1039/c6mb00873a (2017).
32. BRAVO-Group. *Bravo- Powered by TOPMed (Trans-Omics for Precision Medicine) Freeze 8 on GRCh38*, <https://bravo.sph.umich.edu/freeze8/hg38> (2019).
33. Murphy, A. B. et al. Smoking and prostate cancer in a multi-ethnic cohort. *Prostate* **73**, 1518-1528, doi:10.1002/pros.22699 (2013).
34. Scragg, R. The Vitamin D Assessment (ViDA) study - Design and main findings. *J Steroid Biochem Mol Biol* **198**, 105562, doi:10.1016/j.jsbmb.2019.105562 (2020).
35. Shenoy, D., Packianathan, S., Chen, A. M. & Vijayakumar, S. Do African-American men need separate prostate cancer screening guidelines? *BMC Urol* **16**, 19, doi:10.1186/s12894-016-0137-7 (2016).
36. Cooney, K. A. et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. *Urology* **57**, 91-96, doi:10.1016/s0090-4295(00)00873-6 (2001).

37. Preston, M. A. et al. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. *J Clin Oncol* **34**, 2705-2711, doi:10.1200/JCO.2016.66.7527 (2016).

38. Obertova, Z., Hodgson, F., Scott-Jones, J., Brown, C. & Lawrenson, R. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand. *J Rural Health* **32**, 56-62, doi:10.1111/jrh.12127 (2016).

39. Mariner, D. C., Ashley, M., Shepperd, C. J., Mullard, G. & Dixon, M. Mouth level smoke exposure using analysis of filters from smoked cigarettes: a study of eight countries. *Regul Toxicol Pharmacol* **61**, S39-50, doi:10.1016/j.yrtph.2010.05.006 (2011).

40. Penning, T. M. Human aldo-keto reductases and the metabolic activation of polycyclic aromatic hydrocarbons. *Chem Res Toxicol* **27**, 1901-1917, doi:10.1021/tx500298n (2014).

41. Suresh, T. et al. Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population. *Clin Genitourin Cancer* **17**, 139-144, doi:10.1016/j.clgc.2018.12.003 (2019).

42. Dickerman, B. A. et al. A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study. *Metabolites* **10**, doi:10.3390/metabo10030099 (2020).

43. Baillargeon, J. et al. The association of body mass index and prostate-specific antigen in a population-based study. *Cancer* **103**, 1092-1095, doi:10.1002/cncr.20856 (2005).

44. Owen, P. J. et al. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer. *J Cachexia Sarcopenia Muscle* **10**, 1036-1044, doi:10.1002/jcsm.12446 (2019).

45. Brawley, O. W., Thompson, I. M., Jr. & Gronberg, H. Evolving Recommendations on Prostate Cancer Screening. *Am Soc Clin Oncol Educ Book* **35**, e80-87, doi:10.14694/EDBK_157413 (2016).

46. Wang, B. et al. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. *Urol Oncol* **36**, 472.e411-472.e420, doi:10.1016/j.urolonc.2018.07.005 (2018).

47. Lin CH, C. C., Li WM, Wen SC, Huang SP, Li CC, et al. . The Value of Prostate-Specific Antigen-Age Volume Score in Predicting Prostate Cancer in Taiwan. *Urol Sci* **31**, 163-169 (2020).

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryresultsTable12072021.pdf